tiprankstipranks
X4 Pharmaceuticals price target lowered to $4 from $5 at Stifel
The Fly

X4 Pharmaceuticals price target lowered to $4 from $5 at Stifel

Stifel lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $4 from $5 and keeps a Buy rating on the shares. Sequentially flat Xolremdi sales would seem to suggest that inventory build, and not new patient starts, likely accounted for most of Q2 reported sales, notes the analyst, who adds that the pace of patient screening/onboarding is “meaningfully slower” than the firm’s and Street’s expectations. The firm’s reduced price target mostly reflects lower FY24 and later Xolremdi estimates and revised financing assumptions, the analyst noted.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App